GH Frag 176-191 is a carboxyl-terminal fragment of human growth hormone researched for promoting lipolysis and inhibiting lipogenesis without significant effects on blood glucose or IGF-1. It is studied for targeted body composition modulation.

Research Focus:

• Fat loss and adipose metabolism
• Body composition optimization
• Metabolic health

Sources:

Fragment biology (Endocrinology): https://academic.oup.com/endo/article-abstract/128/5/2280/2652622

Obesity/metabolism fragment review (Endocrinology & Metabolism Clinics): https://www.endocrinology.theclinics.com/article/S0889-8529(06)00022-7/fulltext

Human safety (DDDT): https://www.dovepress.com/the-safety-and-tolerability-of-aod9604-in-human-clinical-trials-peer-reviewed-article-DDDT

⚠️ Disclaimer: For research use only. Not intended for human consumption. This information is provided for educational purposes and has not been evaluated by the FDA.